Literature DB >> 14578166

Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

James W Mandell1.   

Abstract

Until recently, the investigation of protein phosphorylation was limited to biochemical studies of enzyme activities in homogenized tissues. The availability of hundreds of phosphorylation state-specific antibodies (PSSAs) now makes possible the study of protein phosphorylation in situ, and is opening many exciting opportunities in investigative and diagnostic pathology. This review illustrates the power of PSSAs, especially in immunohistochemical applications to human disease and animal models. Technical considerations, including antibody specificity and lability of phosphoepitopes, are covered, along with potential pitfalls, illustrated by a case study. In the arena of oncology, PSSAs may prove especially valuable in directly demonstrating the efficacy of chemotherapies targeted at protein kinase cascades. Novel applications of PSSAs are also beginning to reveal molecular mechanisms of inflammatory, degenerative, and toxin-induced diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578166      PMCID: PMC1892416          DOI: 10.1016/S0002-9440(10)63525-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  74 in total

1.  Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state-specific antibodies.

Authors:  X Ouyang; T Gulliford; A Doherty; G C Huang; R J Epstein
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

2.  The enzymatic phosphorylation of proteins.

Authors:  G BURNETT; E P KENNEDY
Journal:  J Biol Chem       Date:  1954-12       Impact factor: 5.157

3.  Adjacent carboxyterminal tyrosine phosphorylation events identify functionally distinct ErbB2 receptor subsets: implications for molecular diagnostics.

Authors:  X Ouyang; G C Huang; A Chantry; R J Epstein
Journal:  Exp Cell Res       Date:  1998-06-15       Impact factor: 3.905

4.  Low initial tau phosphorylation in human brain biopsy samples.

Authors:  J Song; C K Combs; W H Pilcher; L Y Song; A K Utal; P D Coleman
Journal:  Neurobiol Aging       Date:  1997 Sep-Oct       Impact factor: 4.673

5.  Immunohistochemical screening for oncogenic tyrosine kinase activation.

Authors:  K Pulford; G Delsol; G Roncador; S Biddolph; M Jones; D Y Mason
Journal:  J Pathol       Date:  1999-04       Impact factor: 7.996

6.  Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody.

Authors:  M B Flick; E Sapi; P L Perrotta; M G Maher; R Halaban; D Carter; B M Kacinski
Journal:  Oncogene       Date:  1997-05-29       Impact factor: 9.867

7.  Characterization of an antibody that can detect an activated IGF-I receptor in human cancers.

Authors:  M Rubini; C D'Ambrosio; S Carturan; G Yumet; E Catalano; S Shan; Z Huang; M Criscuolo; M Pifferi; R Baserga
Journal:  Exp Cell Res       Date:  1999-08-25       Impact factor: 3.905

8.  Activation of mitogen-activated protein kinase associated with prostate cancer progression.

Authors:  D Gioeli; J W Mandell; G R Petroni; H F Frierson; M J Weber
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

9.  In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms.

Authors:  J W Mandell; I M Hussaini; M Zecevic; M J Weber; S R VandenBerg
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  Active MAP kinase in mitosis: localization at kinetochores and association with the motor protein CENP-E.

Authors:  M Zecevic; A D Catling; S T Eblen; L Renzi; J C Hittle; T J Yen; G J Gorbsky; M J Weber
Journal:  J Cell Biol       Date:  1998-09-21       Impact factor: 10.539

View more
  38 in total

1.  A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.

Authors:  Benoit You; Anthony Brade; Joao M Magalhaes; Lillian L Siu; Amit Oza; Sonya Lovell; Lisa Wang; David W Hedley; Leonardo V Nicacio; Eric X Chen
Journal:  Invest New Drugs       Date:  2010-05-08       Impact factor: 3.850

Review 2.  Chasing phosphohistidine, an elusive sibling in the phosphoamino acid family.

Authors:  Jung-Min Kee; Tom W Muir
Journal:  ACS Chem Biol       Date:  2011-12-09       Impact factor: 5.100

Review 3.  Analysis of mitogen-activated protein kinase activation and interactions with regulators and substrates.

Authors:  Lee Bardwell; Kandarp Shah
Journal:  Methods       Date:  2006-11       Impact factor: 3.608

Review 4.  Antibody validation.

Authors:  Jennifer Bordeaux; Allison Welsh; Seema Agarwal; Elizabeth Killiam; Maria Baquero; Jason Hanna; Valsamo Anagnostou; David Rimm
Journal:  Biotechniques       Date:  2010-03       Impact factor: 1.993

Review 5.  Understanding protein phosphorylation on a systems level.

Authors:  Jimmy Lin; Zhi Xie; Heng Zhu; Jiang Qian
Journal:  Brief Funct Genomics       Date:  2010-01-07       Impact factor: 4.241

Review 6.  Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains.

Authors:  Halliday A Idikio
Journal:  Int J Clin Exp Pathol       Date:  2009-11-25

7.  Development of SH2 probes and pull-down assays to detect pathogen-induced, site-specific tyrosine phosphorylation of the TLR adaptor SCIMP.

Authors:  Lin Luo; Samuel J Tong; Adam A Wall; Tatiana Khromykh; Matthew J Sweet; Jennifer L Stow
Journal:  Immunol Cell Biol       Date:  2017-03-14       Impact factor: 5.126

8.  Quantification of rapid Myosin regulatory light chain phosphorylation using high-throughput in-cell Western assays: comparison to Western immunoblots.

Authors:  Hector N Aguilar; Barbara Zielnik; Curtis N Tracey; Bryan F Mitchell
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

9.  Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.

Authors:  Maëva Lion; Alexandre Harlé; Julia Salleron; Carole Ramacci; Mario Campone; Jean-Louis Merlin
Journal:  Oncol Lett       Date:  2016-07-20       Impact factor: 2.967

10.  Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.

Authors:  Ivette F Emery; Chiara Battelli; Paul L Auclair; Kathleen Carrier; Daniel M Hayes
Journal:  BMC Cancer       Date:  2009-09-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.